N@N

Andrew Fein Maintained (AMLX) at Strong Buy and Held Target at $8 on, Apr 8th, 2024

Andrew Fein of HC Wainwright & Co., Maintained "Amylyx Pharmaceuticals, Inc." (AMLX) at Strong Buy and Held Target at $8 on, Apr 8th, 2024.

Andrew has made no other calls on AMLX in the last 4 months.

There are 6 other peers that have a rating on AMLX. Out of the 6 peers that are also analyzing AMLX, 4 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Joel Beatty of "Baird" Downgraded from Buy to Hold and Decreased Target to $4 on, Monday, March 11th, 2024
• Marc Goodman of "Leerink Partners" Downgraded from Buy to Hold on, Monday, March 11th, 2024
• Chris Shibutani of "Goldman Sachs" Downgraded from Strong Buy to Hold and Decreased Target to $4 on, Monday, March 11th, 2024
• Umer Raffat of "Evercore ISI Group" Downgraded from Buy to Hold on, Friday, March 8th, 2024

These are the ratings of the 2 analyists that currently disagree with Andrew

---

• Neena Bitritto-Garg of "Deutsche Bank" Maintained at Strong Buy with Decreased Target to $8 on, Monday, March 11th, 2024
• Graig Suvannavejh of "Mizuho" Reiterated at Strong Buy with Increased Target to $32 on, Friday, March 8th, 2024

Contributing Sources

---